Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Interest & Investment Income: 2010-2024

Historic Interest & Investment Income for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to -$17.6 million.

  • Ani Pharmaceuticals' Interest & Investment Income fell 102.79% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.7 million, marking a year-over-year decrease of 24.99%. This contributed to the annual value of -$17.6 million for FY2024, which is 34.66% up from last year.
  • Ani Pharmaceuticals' Interest & Investment Income amounted to -$17.6 million in FY2024, which was up 34.66% from -$26.9 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Interest & Investment Income registered a high of -$9.5 million during FY2020, and its lowest value of -$28.1 million during FY2022.
  • Its 3-year average for Interest & Investment Income is -$24.2 million, with a median of -$26.9 million in 2023.
  • Per our database at Business Quant, Ani Pharmaceuticals' Interest & Investment Income plummeted by 135.30% in 2022 and then surged by 34.66% in 2024.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Interest & Investment Income stood at -$9.5 million in 2020, then dropped by 26.13% to -$11.9 million in 2021, then slumped by 135.30% to -$28.1 million in 2022, then rose by 3.96% to -$26.9 million in 2023, then surged by 34.66% to -$17.6 million in 2024.